Prevalence, Clinical Manifestations, Treatment, and Clinical Course of Chronic Urticaria in Elderly: A Systematic Review

Kanokvalai Kulthanan,Chuda Rujitharanawong,Kanyalak Munprom,Suphattra Trakanwittayarak,Phumithep Phumariyapong,Suthasanee Prasertsook,Patompong Ungprasert

DOI: https://doi.org/10.2147/JAA.S379912

2022-10-21

Journal of Asthma and Allergy

Abstract:Kanokvalai Kulthanan, 1 Chuda Rujitharanawong, 1 Kanyalak Munprom, 1 Suphattra Trakanwittayarak, 1 Phumithep Phumariyapong, 1 Suthasanee Prasertsook, 1 Patompong Ungprasert 2 1 Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 2 Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA Correspondence: Patompong Ungprasert, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA, Tel +1 216 986 4000, Fax +1 216 986 4953, Email Purpose: Data specific to the epidemiology, clinical features, and management of chronic urticaria (CU) in the geriatric population remain limited and not well understood. We aim to systematically review the prevalence, clinical manifestations, treatment, and clinical course of elderly patients with CU. Patients and methods: Original articles that included data of elderly (aged > 60 years) with CU that were published until February 2021 were searched in PubMed, Scopus, and Embase using predfefined search terms. Related articles were evaluated according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses recommendations. Results: Among the included 85 studies and 1,112,066 elderly CU patients, most (57.4%) were women. The prevalence of elderly CU in the general population ranged from 0.2– 2.8%, and from 0.7– 33.3% among all CU patients. Compared to adult CU, elderly CU patients had a higher percentage of wheal alone (73.9%), and lower rate of positive autologous serum skin test and atopy. Gastrointestinal diseases were the most common comorbidity (71.9%), and there was a high rate of malignancies and autoimmune diseases. Second generation H 1 -antihistamines were commonly used, and achievement of complete control was most often reported. Omalizumab was prescribed in 59 refractory patients, and a significant response to treatment was reported in most patients. The treatment of comorbidities also yielded significant improvement in CU. Conclusion: Elderly CU was found to be different from adult CU in both clinical and laboratory aspects. H 1 - antihistamines are effective as first-line therapy with minimal side-effects at licensed doses. Treatment of secondary causes is important since the elderly usually have age-related comorbidities. Keywords: prevalence, clinical manifestations, treatment, chronic urticaria, elderly, systematic review People are now living longer due to new innovations in both technology and modern medicine. 1 The result has been a doubling of global life expectancy over the past century, and an increase in the aging population worldwide. 2 The World Health Organization and the United Nations define elderly as age ≥60 years and age ≥65 years, respectively. 3,4 Thus, elderly-specific medical care has become and will continue to be a top priority of global public health. Chronic urticaria (CU) is one of the most common pruritic conditions in the older population. 5,6 CU is characterized by the presence of recurrent wheal, with or without angioedema, occurring at least twice a week for longer than 6 weeks. 7 CU can be classified into two subtypes: chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). 7 The pathogenesis of CU is still unclear, but it is thought to be related to histamine, other mediators, and cytokines that are released from activated mast cells by degranulation. 7–9 Among all patient with CU, 4.1–5.5% are elderly. 10−12 Moreover, several systemic and autoimmune diseases have been reported to be associated with CU in the elderly population, including hypertension, chronic kidney disease, diabetes mellitus, thyroid disease, atopic dermatitis and other allergic diseases, cardiac and cerebral vascular disease, and cancer. 11,13–20 CU can also affect various aspects of patient quality of personal and social life, including sleep disorders, anxiety and depression, sexual dysfunction, and decreased work performance. 21–23 Our current understanding of CU in the elderly is still limited since the number of studies describing the clinical manifestations and responses to treatment of CU in the geriatric population with CU remains comparatively small. The International EAACI/GA 2 LEN/EuroGuiDerm/APAAACI Guideline for the Definition, Classification, Diagnosis and Management of Urticaria recommends second generation H 1 -antihistamine (sgAH 1 ) as the first-line treatment for CU. 7 If disease control is inadequate after 2–4 weeks of treatment, increasing the dose up to 4-fold of the sta -Abstract Truncated-

immunology,allergy,respiratory system